FTC’s Continued Crackdown on Bogus Patents Listed in the Orange Book Will Help
Bring More Affordable Alternatives to American Patients More Quickly





 



CSRXP COMMENDS ADMINISTRATION FOR CHALLENGING MORE THAN 200 OF BIG PHARMA’S
SHAM PATENTS THAT BLOCK COMPETITION AND KEEP DRUG PRICES HIGH

FTC’s Continued Crackdown on Bogus Patents Listed in the Orange Book Will Help
Bring More Affordable Alternatives to American Patients More Quickly



For Immediate Release

May 27, 2025



Contact: Jon Conradi

[email protected] <mailto:[email protected]>



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the
following statement on Tuesday on the Federal Trade Commission (FTC)challenging
<[link removed]>
the validity of more than 200 patents on brand name prescription drugs listed
in the U.S. Food and Drug Administration (FDA)’s Orange Book.



“CSRxP commends the Administration for continuing the FTC’s crackdown on Big
Pharma’s sham patents in the Orange Book that block competition from more
affordable alternatives to high-priced brand name drugs,” said CSRxP executive
director Lauren Aronson. “By challenging sham patents, building on positive
progress to better coordinate among agencies and advancing bipartisan,
market-based solutions in Congress to hold Big Pharma accountable for
anti-competitive practices, policymakers in Washington can deliver greater
competition in the prescription drug marketplace and lower prices for the
American people.”



Learn more on Big Pharma’s patent abuse that blocks competition and keeps drug
prices highHERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>